Evidence map›Paper›PMID 28259922›Full record

ArticleMolecular medicine reports2017

Signal transduction involved in lipoxin A4‑induced protection of tubular epithelial cells against hypoxia/reoxygenation injury.

Sheng-Hua Wu, Ming-Jie Wang, Jing Lü, Xiao-Qing Chen

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Arachidonic Acid Structure and Synthesis.Reviews of physiology, biochemistry and pharmacology · 2027
    Review
  2. A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  3. Article
  4. Therapeutic activity of lipoxin AFrontiers in immunology · 2023
    Article
  5. Lipoxin alleviates oxidative stress: a state-of-the-art review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
  6. Lipoxin A4 Restores Septic Renal FunctionFrontiers in immunology · 2021
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sheng-Hua WuDepartment of Pediatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Ming-Jie WangDepartment of Pediatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Jing LüDepartment of Pediatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Xiao-Qing ChenDepartment of Pediatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have reported that lipoxin A4 (LXA4) may exert a renoprotective effect on ischemia/reperfusion injury in various animal models. The underlying mechanism of LXA4‑induced renoprotection during ischemia/reperfusion injury remains to be elucidated. The present study investigated LXA4‑induced protection on renal tubular cells subjected to hypoxia/reoxygenation (H/R) injury, and determined the effects of peroxisome proliferator‑activated receptor‑γ (PPARγ) and heme oxygenase‑1 (HO‑1) on LXA4 treatment. HK‑2 human tubular epithelial cells exposed to H/R injury were pretreated with LXA4, signal molecule inhibitors or the HO‑1 inhibitor zinc protoporphyrin‑IX, or were transfected with PPARγ small interfering RNA (siRNA) or nuclear factor E2‑related factor 2 (Nrf2) siRNA. The protein and mRNA expression levels of PPARγ and HO‑1 were analyzed using western blotting and reverse transcription‑quantitative polymerase chain reaction. Binding activity of Nrf2 to the HO‑1 E1 enhancer was determined using chromatin immunoprecipitation. Nrf2 binding to the HO‑1 antioxidant responsive element (ARE) was assessed using electrophoretic mobility shift assay. Preincubation of cells with LXA4 exposed to H/R injury led to a decreased production of inducible nitrogen oxide synthase, malondialdehyde, γ‑glutamyl transpeptidase, leucine aminopeptidase and N‑acetyl‑β‑glucosaminidase. In addition, LXA4 pretreatment increased cell viability, protein and mRNA expression levels of PPARγ and HO‑1 and PPARγ and HO‑1 promoter activity. SB20358 is a p38 mitogen‑activated protein kinase (p38 MAPK) pathway inhibitor, which reduced LXA4‑induced PPARγ expression levels. LXA4 treatment upregulated p38 MAPK activation, Nrf2 nuclear translocation and increased binding activity of Nrf2 to HO‑1 ARE and E1 enhancer in cells exposed to H/R injury. Transfection of the cells with PPARγ siRNA reduced the LXA4‑induced Nrf2 translocation. Transfection of the cells with PPARγ siRNA or Nrf2 siRNA also reduced the LXA4‑induced increase in HO‑1 expression. In conclusion, LXA4‑induced protection of renal tubular cells against H/R injury was associated with the induction of PPARγ and HO‑1, via activation of the p38 MAPK pathway, as well as Nrf2 nuclear translocation and binding to HO‑1 ARE and E1 enhancer. Therefore, LXA4‑induced renoprotection is associated with activation of the p38 MAPK/PPARγ/Nrf2‑ARE/HO‑1 pathway.

Indexed as

Antioxidant Response ElementsCell HypoxiaCell SurvivalCytoprotectionEpithelial Cellsgamma-GlutamyltransferaseHeme Oxygenase-1HumansKidney TubulesLipoxinsMalondialdehydeNF-E2-Related Factor 2Nitric Oxide Synthase Type IIOxygenp38 Mitogen-Activated Protein KinasesPPAR gammagamma-GlutamyltransferaseHeme Oxygenase-1lipoxin A4LipoxinsMalondialdehydeNF-E2-Related Factor 2Nitric Oxide Synthase Type IIOxygenp38 Mitogen-Activated Protein KinasesPPAR gammaSuperoxide Dismutase

Identifiers

PMID28259922
PMCPMC5365021
OpenAlexW2588488537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.